News & Events

• June 29, 2022
  

  C-Path and Replica Analytics Collaboration Aims to Accelerate Rare Disease Research

  C-Path and Replica Analytics, an Aetion company, announced today a new partnership that involves leveraging synthetic data to further catalyze the generation of actionable solutions to accelerate drug development for rare diseases.

• June 7, 2022
  

  C-Path and MitoAction Announce Data Sharing Agreement to Support Treatment Development in Mitochondrial Disease

  C-Path and MitoAction today announced a joint collaboration to incorporate patient data for rare mitochondrial disorders into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).

• May 31, 2022
  

  FSHD Society and Critical Path Institute Collaborate to Collect Clinical Trial Data

  The FSHD Society, a research-focused patient advocacy nonprofit dedicated to bringing treatments to patients affected by facioscapulohumeral muscular dystrophy (FSHD), has partnered with Critical Path Institute (C-Path) to facilitate the integration of clinical trial data from the control arm of various FSHD-related clinical studies into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP ^®). These data will come from several companies that have sponsored clinical trials in FSHD.

• April 28, 2022
  

  C-Path to Lead Novel Pre-Consortium Framework for Optimizing the Rare and Orphan Medical Product Lifecycle

  C-Path, in collaboration with one of the industry’s prominent rare and orphan (R&O) thought leaders, Maryna Kolochavina, Pharm.D., Ph.D., today announced the launch of unique pre-consortium collaboration, bringing together industry leaders and stakeholders to accelerate and standardize key constructs for the efficient development, approval and access to R&O medical products.

• April 5, 2022
  

  New logo! Rare Disease Cures Accelerator-Data and Analytics Platform has a new look!

  C-Path’s RDCA-DAP team is excited to unveil its new logo for the Rare Disease Cures Accelerator-Data and Analytics Platform initiative. The logo is a collaboration between C-Path, the National Organization of Rare Disorders (NORD) and the rare disease community — who graciously answered C-Path and NORD’s call to weigh in on the final logos. “We’re beyond happy about where we landed with this logo,” said C-Path SVP and RDCA-DAP Lead Jeff Barrett, Ph.D., F.C.P. “The logo is a great representation of the data collaboration among the rare disease community to help speed up and advance treatments and cures for rare diseases.”